Compare Futu Holdings Ltd (FUTU) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Summit Therapeutics Inc — how do they compare? Futu Holdings Ltd trades at $113.47 (market cap $15.25B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Futu Holdings Ltd and Summit Therapeutics Inc are close in size by market cap, and Futu Holdings Ltd pays a 2.39% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Summit Therapeutics Inc for 16 Days on average.
| FUTU | SMMT | |
|---|---|---|
Market Cap | $15.25B | $13.71B |
Volume | 812,567 | 6,173,057 |
Sector | Financials | Health |
52-Week High | $199.04 | $26.38 |
52-Week Low | $89.76 | $12.43 |
Typical Hold Time | 34 Days | 16 Days |
Enterprise Value | $15.59B | $13.04B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUTU trades at $113.71, up 3.67% today, with a bearish technical signal but strong fundamentals including a 10.86 P/E ratio and 42.92% net margin. Revenue grew to $22.85B in 2025, and cash flow surged to $31.02B in 2024. Recent news highlights expansion efforts like the Moomoo X partnership and a class action lawsuit deadline.
The outlook is mixed: analysts see a 33.7% upside (Zacks, 2026-09-10), but technicals and legal risks weigh. Investment opportunity lies in valuation and growth; risks include lawsuit uncertainty and competitive pressures. Earnings beat in Q2 2026 supports momentum, but Q1 2026 miss shows volatility.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
